Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.

    ... such as thrombosis. Eculizumab , a humanized monoclonal antibody against the C5 complement protein, is the only effective drug ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab.

    ... labor and fetal loss. Eculizumab , a humanized monoclonal antibody directed against the terminal complement protein C5, has ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

    ... yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by donor stem cell transplant in ...

    Clinical Trial last updated 04/28/2016 - 1:11pm.

  4. Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Sy

    ... the side effects and best dose of iodine I 131monoclonal antibody BC8 when given together with fludarabine phosphate, ... rejecting the donor's stem cells . Also, radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody BC8, ...

    Clinical Trial last updated 04/28/2016 - 1:01pm.

  5. Small-molecule Factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

    ... that are treated with eculizumab , a humanized monoclonal antibody against the terminal complement component C5. Eculizumab must be ...

    Research Article last updated 11/28/2016 - 11:42am.

  6. Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations

    ... The development of eculizumab , a humanized monoclonal antibody directed against the terminal complement protein C5, has resulted ...

    Research Article last updated 09/13/2016 - 1:53pm.

  7. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study

    ... be controlled with eculizumab , a humanized monoclonal antibody that binds complement protein C5. We report here a retrospective ...

    Research Article last updated 04/29/2016 - 10:21am.

  8. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria

    ... namely complement blockade through the anti-C5 monoclonal antibody eculizumab . This brief review focuses on two specific ...

    Research Article last updated 06/07/2016 - 10:56am.

  9. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... (Bacillus Tuberculosis). Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered ...

    Clinical Trial last updated 05/14/2018 - 1:57pm.

  10. A Rare Genetic Polymorphism in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab by Nine Japanese Patients with PNH

    Original Publication Date:  Tuesday, January 1, 2013 Note: This review is based upon a presentation at the 2012 American Society of Hematology ...

    Research Review last updated 05/02/2016 - 9:25am.